Lucid Diagnostics Inc
NASDAQ:LUCD 4:00:00 PM EDT
| Market Cap (Intraday) | 114.68M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.10 |
| 50-Day MA | $1.25 |
| 200-Day MA | $1.10 |
Lucid Diagnostics Inc Stock, NASDAQ:LUCD
360 Madison Avenue, 25th Floor, New York, New York 10017
United States of America
Phone: +1.212.949.4319
Number of Employees: 70
Description
Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.